Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L)

Trial Profile

Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary) ; Pegfilgrastim
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms DRAGON
  • Most Recent Events

    • 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer
    • 05 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top